4,5-dihydro-1-(3-ethoxy-α-ethylbenzyl)-7-(5-pyrimidinylmethoxy)-[1H]-benz[g]indazole-3-carboxylic acid | 219705-77-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 4,5-dihydro-1-(3-ethoxy-α-ethylbenzyl)-7-(5-pyrimidinylmethoxy)-[1H]-benz[g]indazole-3-carboxylic acid
• 英文别名: 1H-Benz(g)indazole-3-carboxylic acid, 1-(1-(3-ethoxyphenyl)propyl)-4,5；1-[1-(3-ethoxyphenyl)propyl]-7-(pyrimidin-5-ylmethoxy)-4,5-dihydrobenzo[g]indazole-3-carboxylic acid
• CAS: 219705-77-8
• 化学式: C₂₈H₂₈N₄O₄
• 分子量: 484.555
• InChiKey: GEVQMCFWDDZLMU-UHFFFAOYSA-N

物化性质

• 沸点：
  725.6±60.0 °C(Predicted)
• 密度：
  1.30±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  36
• 可旋转键数：
  9
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  99.4
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  4,5-dihydro-1-(3-ethoxy-α-ethylbenzyl)-7-(5-pyrimidinylmethoxy)-[1H]-benz[g]indazole-3-carboxylic acid 、 water ethanol 在 sodium hydroxide 作用下， 以 水 为溶剂， 以80%的产率得到4,5-dihydro-1-(3-ethoxy-α-ethylbenzyl)-7-(5-pyrimidinylmethoxy)-[1H]-benz[g]indazole-3-carboxylic acid sodium salt
  参考文献：
  名称：

  4,5-dihydro-[1H]-benz[g]indazole-3-carboxylic acid derivatives

  摘要：

  以下公式所代表的4,5-二氢-[1H]-苯[g]吲唑-3-羧酸衍生物，或其盐，对内皮素受体具有出色的拮抗作用，并可用作预防或治疗高血压、心绞痛、心肌梗死、脑梗死、脑血管收缩、肾功能不全、肝功能障碍、动脉硬化和PTCA术后再狭窄等疾病的药物。其中Ar代表可选择取代的芳基，R1代表氢原子、可选择取代的较低烷基、可选择取代的芳基、可选择取代的环烷基或可选择取代的杂环基。

  公开号：

  US06291485B1

文献信息

• 4,5-DIHYDRO- 1H]-BENZ g]INDAZOLE-3-CARBOXYLIC ACID DERIVATIVES
  申请人：TEIKOKU HORMONE MFG. CO., LTD.

  公开号：EP1002797A1

  公开（公告）日：2000-05-24

  4,5-Dihydro-[1H]-benz[g]indazole-3-carboxylic acid derivatives represented by the following formula, or their salts, have excellent antagonism to endothelin receptors and are useful as preventives or remedies for diseases such as hypertension, angina pectoris, myocardial infarction, brain infarction, cerebrovascular contraction, renal insufficiency, hepatic dysfunction, arteriosclerosis and post-PTCA restenosis. wherein Ar represents an optionally substituted aryl group, and R1 represents a hydrogen atom, an optionally substituted lower alkyl group, an optionally substituted aryl group, an optionally substituted cycloalkyl group or an optionally substituted heterocyclic group.

  下式所代表的 4,5-二氢-[1H]-苯并[g]吲唑-3-羧酸衍生物或其盐类对内皮素受体具有极好的拮抗作用，可作为高血压、心绞痛、心肌梗塞、脑梗塞、脑血管收缩、肾功能不全、肝功能障碍、动脉硬化和 PTCA 术后再狭窄等疾病的预防或治疗药物。 其中 Ar 代表任选取代的芳基，R1 代表氢原子、任选取代的低级烷基、任选取代的芳基、任选取代的环烷基或任选取代的杂环基。
• TREATMENTS OF B-CELL PROLIFERATIVE DISORDERS
  申请人：Rickles Richard

  公开号：US20090053168A1

  公开（公告）日：2009-02-26

  The invention provides compositions and methods for the treatment of B-cell proliferative disorders that employ an A2A receptor agonist or one or more PDE inhibitors. The methods and compositions may further include an antiproliferative compound.
• COMBINATIONS FOR THE TREATMENT OF B-CELL PROLIFERATIVE DISORDERS
  申请人：Rickles Richard

  公开号：US20090047243A1

  公开（公告）日：2009-02-19

  The invention features compositions and methods employing combinations of an A2A receptor agonist and a PDE inhibitor for the treatment of a B-cell proliferative disorder, e.g., multiple myeloma.
• BETA ADRENERGIC RECEPTOR AGONISTS FOR THE TREATMENT OF B-CELL PROLIFERATIVE DISORDERS
  申请人：RICKLES Richard

  公开号：US20100009934A1

  公开（公告）日：2010-01-14

  The invention features a method of treating a B-cell proliferative disorder by administering to a patient a BAR agonist, e.g., formulated for administration by a route other than inhalation (such as for oral or intravenous administration), in an amount effective to treat the B-cell proliferative disorder. The BAR agonist may be administered as a monotherapy or in combination with one or more other agents, e.g., a PDE inhibitor, an A2A receptor agonist, or an antiproliferative compound, in amounts that together are effective to treat the B-cell proliferative disorder. The invention further features pharmaceutical compositions and kits including a BAR agonist, alone or in combination with additional agents, for the treatment of a B-cell proliferative disorder.
• Method for Control of Drug Elution Rate and Composition for Coating of Drug-Eluting Stent
  申请人：Azuma Hiroshi

  公开号：US20100040666A1

  公开（公告）日：2010-02-18

  Disclosed are a method for controlling the elution of a drug from a stent and a drug-eluting stent capable of reducing the restenosis rate after therapy. A coating composition for a drug-eluting stent comprising an endothelin receptor antagonist and a copolymer of 2-methacryloyloxyethyl phosphorylcholine and n-butyl methacrylate. The elution of the endothelin receptor antagonist from the coating composition can be controlled by varying the ratio of 2-methacryloyloxyethyl phosphorylcholine to n-butyl methacrylate in the copolymer.